- Here are the major earnings before the open Tuesday
May 11, 2026
Major earnings expected before the bell on Tuesday include:
* JD.com (JD [https://seekingalpha.com/symbol/JD])
* Sea Limited (SE [https://seekingalpha.com/symbol/SE])
* D-Wave Quantum (QBTS [https://seekingalpha.com/symbol/QBTS])
* Lithium Argentina AG (LAC [https://seekingalpha.com/symbol/LAC])
* Under Armour (UAA [https://seekingalpha.com/symbol/UAA])
Other earnings slated for release before Tuesday's open include:
* ACHV [https://seekingalpha.com/symbol/ACHV], AG [https://seekingalpha.com/symbol/AG], ALLT [https://seekingalpha.com/symbol/ALLT], AMTM [https://seekingalpha.com/symbol/AMTM], ARMK [https://seekingalpha.com/symbol/ARMK], ARVN [https://seekingalpha.com/symbol/ARVN], BAYZF [https://seekingalpha.com/symbol/BAYZF], BETA [https://seekingalpha.com/symbol/BETA], BIOX [https://seekingalpha.com/symbol/BIOX], BRSL [https://seekingalpha.com/symbol/BRSL], BWEN [https://seekingalpha.com/symbol/BWEN], CAMT [https://seekingalpha.com/symbol/CAMT], CWCO [https://seekingalpha.com/symbol/CWCO], DCO [https://seekingalpha.com/symbol/DCO], ETOR [https://seekingalpha.com/symbol/ETOR], FUJIY [https://seekingalpha.com/symbol/FUJIY], GHI [https://seekingalpha.com/symbol/GHI], HUYA [https://seekingalpha.com/symbol/HUYA], IMNN [https://seekingalpha.com/symbol/IMNN], KBCSY [https://seekingalpha.com/symbol/KBCSY], KOPN [https://seekingalpha.com/symbol/KOPN], KT [https://seekingalpha.com/symbol/KT], LAR [https://seekingalpha.com/symbol/LAR], LEGN [https://seekingalpha.com/symbol/LEGN], MURGY [https://seekingalpha.com/symbol/MURGY], NLST [https://seekingalpha.com/symbol/NLST], NUWE [https://seekingalpha.com/symbol/NUWE], OGI [https://seekingalpha.com/symbol/OGI], ONON [https://seekingalpha.com/symbol/ONON], Q [https://seekingalpha.com/symbol/Q], RDY [https://seekingalpha.com/symbol/RDY], SATL [https://seekingalpha.com/symbol/SATL], SFL [https://seekingalpha.com/symbol/SFL], SMEGF [https://seekingalpha.com/symbol/SMEGF], SNBR [https://seekingalpha.com/symbol/SNBR], TE [https://seekingalpha.com/symbol/TE], TIGO [https://seekingalpha.com/symbol/TIGO], TME [https://seekingalpha.com/symbol/TME], TONX [https://seekingalpha.com/symbol/TONX], UA [https://seekingalpha.com/symbol/UA], VERI [https://seekingalpha.com/symbol/VERI], VG [https://seekingalpha.com/symbol/VG], ZBRA [https://seekingalpha.com/symbol/ZBRA]
* For Seeking Alpha's full earnings season calendar, click here [https://seekingalpha.com/earnings/earnings-calendar].
- Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026
May 5, 2026 · globenewswire.com
SEATTLE and VANCOUVER, British Columbia, May 05, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced it will report its first quarter 2026 financial results and provide a corporate update on Tuesday, May 12, 2026, at 8:30 AM EDT.
- ACHIEVE LIFE SCIENCES TO ANNOUNCE FIRST QUARTER 2026 FINANCIAL RESULTS AND HOST CONFERENCE CALL AND WEBCAST ON MAY 12, 2026
May 5, 2026
SEATTLE AND VANCOUVER, BRITISH COLUMBIA, MAY 05, 2026 (GLOBE NEWSWIRE) -- ACHIEVE LIFE SCIENCES, INC. (NASDAQ: ACHV), A LATE-STAGE SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON THE GLOBAL DEVELOPMENT AND COMMERCIALIZATION OF CYTISINICLINE AS A TREATMENT OF NICOTINE DEPENDENCE, TODAY ANNOUNCED IT WILL REPORT ITS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON TUESDAY, MAY 12, 2026, AT 8:30 AM EDT.
- Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Average Rating of “Buy” by Brokerages
Apr 24, 2026 · defenseworld.net
Achieve Life Sciences, Inc. (NASDAQ: ACHV - Get Free Report) has been assigned an average recommendation of "Buy" from the six ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and two have issued a strong buy rating
- Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors
Apr 16, 2026 · globenewswire.com
Achieve Names Two New Exemplary Healthcare Leaders to its Board of Directors New Leadership and Financing, up to $354 Million ($180 Million Upfront and $174 Million Dependent on the Exercise of Milestone Warrants), Strengthen Achieve's Position to Execute Development and Launch of Cytisinicline, if Approved, as the First New Treatment for Nicotine Dependence in Two Decades SEATTLE and VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV) today announced it has appointed Andrew D. Goldberg, MD, as Chief Executive Officer and as a member of the Board of Directors, effective following the closing of Achieve's recently announced financing.
- ACHIEVE LIFE SCIENCES ANNOUNCES APPOINTMENT OF ANDREW D. GOLDBERG, MD, AS CHIEF EXECUTIVE OFFICER AND TO THE BOARD OF DIRECTORS
Apr 16, 2026
ACHIEVE NAMES TWO NEW EXEMPLARY HEALTHCARE LEADERS TO ITS BOARD OF DIRECTORS NEW LEADERSHIP AND FINANCING, UP TO $354 MILLION ($180 MILLION UPFRONT AND $174 MILLION DEPENDENT ON THE EXERCISE OF MILESTONE WARRANTS), STRENGTHEN ACHIEVE'S POSITION TO EXECUTE DEVELOPMENT AND LAUNCH OF CYTISINICLINE, IF APPROVED, AS THE FIRST NEW TREATMENT FOR NICOTINE DEPENDENCE IN TWO DECADES SEATTLE AND VANCOUVER, BRITISH COLUMBIA, APRIL 16, 2026 (GLOBE NEWSWIRE) -- ACHIEVE LIFE SCIENCES, INC. (NASDAQ: ACHV) TODAY ANNOUNCED IT HAS APPOINTED ANDREW D. GOLDBERG, MD, AS CHIEF EXECUTIVE OFFICER AND AS A MEMBER OF THE BOARD OF DIRECTORS, EFFECTIVE FOLLOWING THE CLOSING OF ACHIEVE'S RECENTLY ANNOUNCED FINANCING.
- Achieve Life Sciences Announces Up to $354 Million Private Placement
Apr 16, 2026 · globenewswire.com
$180 Million Financing Upfront with Up to an Additional $174 Million from Warrants Exercisable Within 20 Days of FDA Approval
- ACHIEVE LIFE SCIENCES ANNOUNCES UP TO $354 MILLION PRIVATE PLACEMENT
Apr 16, 2026
$180 MILLION FINANCING UPFRONT WITH UP TO AN ADDITIONAL $174 MILLION FROM WARRANTS EXERCISABLE WITHIN 20 DAYS OF FDA APPROVAL
- Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions
Apr 15, 2026 · globenewswire.com
Adare Partnership Provides Supply Chain Redundancy and U.S.-based Manufacturing Capability Company Reiterates Guidance - If Approved, Cytisinicline Commercial Launch Expected in First Half of 2027 SEATTLE and VANCOUVER, British Columbia, April 15, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced significant operational progress including the transfer of cytisinicline manufacturing to U.S.-based Adare Pharma Solutions (Adare). Achieve has now completed the analytical method transfer to Adare's manufacturing facility in Vandalia, Ohio.
- ACHIEVE LIFE SCIENCES ANNOUNCES OPERATIONAL PROGRESS INCLUDING COMPLETION OF TECHNOLOGY TRANSFER TO ADARE PHARMA SOLUTIONS
Apr 15, 2026
ADARE PARTNERSHIP PROVIDES SUPPLY CHAIN REDUNDANCY AND U.S.-BASED MANUFACTURING CAPABILITY COMPANY REITERATES GUIDANCE - IF APPROVED, CYTISINICLINE COMMERCIAL LAUNCH EXPECTED IN FIRST HALF OF 2027 SEATTLE AND VANCOUVER, BRITISH COLUMBIA, APRIL 15, 2026 (GLOBE NEWSWIRE) -- ACHIEVE LIFE SCIENCES, INC. (ACHIEVE OR THE COMPANY) (NASDAQ: ACHV), A LATE-STAGE SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON THE GLOBAL DEVELOPMENT AND COMMERCIALIZATION OF CYTISINICLINE AS A TREATMENT OF NICOTINE DEPENDENCE, TODAY ANNOUNCED SIGNIFICANT OPERATIONAL PROGRESS INCLUDING THE TRANSFER OF CYTISINICLINE MANUFACTURING TO U.S.-BASED ADARE PHARMA SOLUTIONS (ADARE). ACHIEVE HAS NOW COMPLETED THE ANALYTICAL METHOD TRANSFER TO ADARE'S MANUFACTURING FACILITY IN VANDALIA, OHIO.
